Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)-Reference-Cited by-同舟云学术

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)

Published:2021-06-16 Issue:1 Volume:17 Page:35-44
ISSN:1999-8627
Container-title:Tumors of female reproductive system
language:
Short-container-title:Opuholi ženskoj reproduktivnoj sistemy

Author:

Nasretdinov A. F.¹^ORCID,Pushkarev A. V.¹^ORCID,Lipatov O. N.²^ORCID,Sultanbaeva N. I.¹^ORCID,Musin Sh. I.¹^ORCID,Menshikov K. V.³^ORCID,Izmailov A. A.³^ORCID,Pushkarev V. A.³^ORCID,Galeev M. G.¹^ORCID,Muginov R. R.¹^ORCID,Valiakhmedov R. B.¹^ORCID,Sakaeva D. D.²^ORCID,Sultanbaev A. V.¹^ORCID

Affiliation:

1. Republican Clinical Oncology Dispensary, Ministry of Healthcare of Republic of Bashkortostan

2. Bashkir State Medical University, Ministry of Health of Russia

3. Republican Clinical Oncology Dispensary, Ministry of Healthcare of Republic of Bashkortostan; Bashkir State Medical University, Ministry of Health of Russia

Abstract

Descripton of metastatic HER2-positive breast cancer clinical case is introduced, multilineal strategy basing on clinical situation and disease features is justified, justification of the choice of anti-HER2 treatment in every line is made, in compliance with russian and foreigh oncology associations guidelines, along with comparance of rutine treatment results and randomised trials data.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference19 articles.

1. Pushkarev A.V., Sultanbaeva N.I., Pushkarev V.A. i dr. Spektr i chastota mutatsii v genakh BRCA1, BRCA2, CHEK2, PALB2 i RAD50 u patsientok s rakom molochnoi zhelezy v Respublike Bashkortostan. Kazanskii meditsinskii zhurnal 2020;101(5):691–7. [Pushkarev A.V., Sultanbaeva N.I., Pushkarev V.A. et al. Spectrum and frequency of mutations in the genes BRCA1, BRCA2, CHEK2, PALB2, and RAD50 among patients with breast cancer in the Republic of Bashkortostan. Kazanskiy meditsinskiy zhurnal = Kazan Medical Journal 2020;101(5):691–7. (In Russ.)]. DOI: 10.17816/KMJ2020-691.

2. Sultanbaev A., Minniakhmetov I., Sultanbaeva N. et al. 25P Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia. Ann Oncol 2020;31:S1250. DOI: 10.1016/j.annonc.2020.10.045.

3. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2019 godu. Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shakhazadovoi. M.: MNIOI im. P.A. Gertsena – filial FGBU «Natsional'nyi meditsinskii issledovatel'skii tsentr radiologii» Minzdrava Rossii, 2020. 239 s. [Situation with cancer care in Russia in 2019. Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shchakhzadova. Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 2020. 239 p. (In Russ.)].

4. Nasretdinov A.F., Sultanbaeva N.I., Musin Sh.I. i dr. Uroven' opukhol'infil'triruyushchikh limfotsitov i PD-status kak vozmozhnye prognosticheskie markery vyzhivaemosti i effektivnosti terapii pri trizhdy negativnom rake molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy 2020;16(1):65–70. [Nasretdinov A.F., Sultanbaeva N.I., Musin Sh.I. et al. Level of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and treatment efficacy in triple-negative breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of female reproductive system 2020;16(1):65–70. (In Russ.)]. DOI: 10.17650/1994-4098-2020-16-1-65-70.

5. Ross J.S., Fletcher J.A. The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3(4):237–52.